Casirivimab/imdevimab showed no clear difference in all‐cause mortality by day 30 compared with placebo (low certainty).
Azithromycin showed no clear difference in all‐cause mortality at day 28 compared with placebo or standard of care alone (high certainty).
Azithromycin showed no clear difference in all‐cause mortality at day 28 compared with placebo or standard of care alone (low certainty).
Metoprolol showed no clear difference in all‐cause mortality, 30 days1 compared with placebo (low certainty).
Antibiotics showed no clear difference in all‐cause mortality at maximum compared with placebo or no intervention (high certainty).
Glucocorticoid showed no clear difference in all‐cause mortality at longest compared with placebo (moderate certainty).
Beta‐blockers probably leads to lower all‐cause mortality at maximum compared with placebo or no intervention (moderate certainty).
Metoprolol showed no clear difference in all‐cause mortality, 6 months1 compared with placebo (low certainty).
It is very uncertain whether vitamin C supplementation changes all‐cause mortality Physicians compared with placebo (very low certainty).
Heparin showed no clear difference in neonatal mortality (all‐cause) compared with placebo/no treatment (low certainty).
It is very uncertain whether sarilumab changes all‐cause mortality D60 or more compared with standard care/placebo (very low certainty).
It is very uncertain whether clazakizumab changes all‐cause mortality D60 or more compared with standard care/placebo (very low certainty).
It is very uncertain whether siltuximab changes all‐cause mortality D60 or more compared with standard care/placebo (very low certainty).
It is very uncertain whether levilimab changes all‐cause mortality D60 or more compared with standard care/placebo (very low certainty).
Tociliuzumab showed no clear difference in all‐cause mortality D60 or more compared with standard care/placebo (low certainty).
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in all‐cause mortality (by day 28) compared with saline placebo (low certainty).
Fluvoxamine plus standard care showed no clear difference in all‐cause mortality (at day 28) compared with placebo plus standard care (low certainty).
It is very uncertain whether canakinumab changes all‐cause mortality D60 or above compared with standard care/placebo (very low certainty).
It is very uncertain whether anakinra changes all‐cause mortality D60 or above compared with standard care/placebo (very low certainty).